Evidence map›Paper›PMID 39563215›Full record

ArticleCombinatorial chemistry & high throughput screening2025

Huazhi Rougan Granule Alleviates Liver and Intestinal Damage in Non-Alcoholic Fatty Liver Disease by Regulating miR-122 Expression and TLR4/MyD88/NF-κB Pathway Activation.

Ping Xie, Xiaowei Jin, Chan Li, Kun Lv, Ming Deng

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Combinatorial chemistry & high throughput screening, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Ping XieDepartment of Traditional Chinese Medicine, Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan 430060, P. R, China.
Xiaowei JinDepartment of Integrated Traditional Chinese and Western Medicine, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming 650019, Yunnan, China.
Chan LiDepartment of Traditional Chinese Medicine, Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan 430060, P. R, China.
Kun LvDepartment of Traditional Chinese Medicine, Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan 430060, P. R, China.
Ming DengDepartment of Orthopedics, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, China.

Funding

Innovative Seed Funds of the Medical College of Wuhan University TFZZ2018027Wuhan Medical Research Project (Youth Project) WZ19Q02
6 · The paper itself

Abstract

purposemiR-122 is upregulated in non-alcoholic fatty liver disease (NAFLD) liver tissue, and knockdown of miR-122 protects hepatocytes from lipid metabolism disorders. This study aimed to investigate whether Huazhi Rougan Granule (HRG) alleviates NAFLD liver and intestinal injury by regulating the miR-122-mediated TLR4/MyD88/NF-κB pathway.

methodsRats with NAFLD were constructed by high-fat feeding. Serum levels of total cholesterol (TC), triglycerides (TG), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were measured using a fully automated biochemical instrument. Histopathological changes in the liver and small intestine were observed by HE staining. QRT-PCR detected the expression level of miR-122 in the liver tissues. The protein expression of TLR4, MyD88, NF- κB p65, and p-p65 in liver tissues was detected by western blotting.

resultsHRG slowed down the weight gain of NAFLD rats, decreased (P<0.05) the levels of TC, TG, ALT, AST, TNF-α, IL-1β, IL-6, LPS, and Hpt, improved the pathological status of liver and small intestine tissues, upregulated (P<0.05) the expression of ZO-1 and Occludin, downregulated (P<0.05) the protein expression of TLR4, MyD88, and p-p65, and inhibited (P<0.05) the expression of miR-122.

conclusionHRG may alleviate hepatic and intestinal injuries in rats with NAFLD by regulating the miR-122-mediated TLR4/MyD88/NF-κB pathway.

Indexed as

Drugs, Chinese HerbalLiverMicroRNAsNon-alcoholic Fatty Liver DiseaseAnimalsIntestinesMaleMyeloid Differentiation Factor 88NF-kappa BRatsRats, Sprague-DawleySignal TransductionToll-Like Receptor 4Drugs, Chinese HerbalMicroRNAsMIRN122 microRNA, ratMyd88 protein, ratMyeloid Differentiation Factor 88NF-kappa BTlr4 protein, ratToll-Like Receptor 4aspartate aminotransferase.intestinal injurylivermiR-122Non-alcoholic fatty liverTLR4/MyD88/NF-κB pathway

Identifiers

PMID39563215

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.